Posted On: November 07, 2014
Dr. Brenda Gallie, a world-renowned ophthalmologist (eye specialist), has recently retired from research. She held a Senior Scientist appointment at the Princess Margaret Cancer Centre from 1999 to the end of August 2014. Dr. Gallie’s research was focused on elucidating the biological mechanisms underpinning a rare form of eye cancer that afflicts children, known as retinoblastoma.
During her 40-year research career, Dr. Gallie made several important discoveries that have contributed to improvements in the diagnosis and treatment of retinoblastoma. In 1985, Dr. Gallie and her collaborators were the first to identify genetic changes that predispose children to retinoblastoma. These seminal findings were published in the prestigious journal Nature. Using this genetic information, Dr. Gallie developed a highly sensitive and cost-effective diagnostic tool for the early identification of children at risk for developing retinoblastoma. Moreover, Dr. Gallie’s research contributed to improved treatment for this cancer by defining the biological mechanisms that enable tumours to resist treatment and persist in the eye.
Although Dr. Gallie has ceased her research activities, she will continue working as an ophthalmologist at The Hospital for Sick Children and leading One World Retinoblastoma, a network that she founded to facilitate the early diagnosis and treatment of retinoblastoma in developing countries.
During her 40-year research career, Dr. Gallie made several important discoveries that have contributed to improvements in the diagnosis and treatment of retinoblastoma. In 1985, Dr. Gallie and her collaborators were the first to identify genetic changes that predispose children to retinoblastoma. These seminal findings were published in the prestigious journal Nature. Using this genetic information, Dr. Gallie developed a highly sensitive and cost-effective diagnostic tool for the early identification of children at risk for developing retinoblastoma. Moreover, Dr. Gallie’s research contributed to improved treatment for this cancer by defining the biological mechanisms that enable tumours to resist treatment and persist in the eye.
Although Dr. Gallie has ceased her research activities, she will continue working as an ophthalmologist at The Hospital for Sick Children and leading One World Retinoblastoma, a network that she founded to facilitate the early diagnosis and treatment of retinoblastoma in developing countries.
Comments